#bladder-cancer

#bladder-cancer

Clinical trials of the drug have shown that people with bladder cancer that has spread (metastasised) live up to twice as long when given the combination antibody treatment when compared with those given normal chemotherapy. One trial also found that almost 30% of patients had no detectable traces of cancer in their body following treatment with enfortumab vedotin and pembrolizumab, compared with only 12.5% with chemotherapy.

We removed the tumor. It was very high-grade and invading through the bladder wall. Not into the muscle layer, something we call very high-risk, non-muscle invasive bladder cancer.